Prenumeration
STENOCARE announced on November 26th the STENOCARE 3.0 Strategy, which means that the company will focus on trading prescription-based medical cannabis sourced from suppliers and exit the production activities at STENOCARE’s own indoor cultivation facility. The decision is based on prolonged and uncertain approval timelines with the Danish Medicines Agency, which creates difficulties in establishing a reliable timeline for the facility's approval. This exit will eliminate approximately DKK 18m in cost obligations over the next six years.
Read Analyst Group’s comment here
About Analyst Group: One of Sweden's leading equity research boutiques with focus on small and medium-sized listed companies.
Read more about Analyst Group
This is a press release from Analyst Group regarding the publication of a comment on STENOCARE. Readers may assume that Analyst Group has received compensation for making the comment. The Company has not been given an opportunity to influence the parts where Analyst Group has had opinions about the Company, future valuation or anything else that could be considered a subjective assessment.